BACKGROUND: Alemtuzumab is effective in @entity3118 -refractory @entity1 with @entity1072 . We performed a phase 2 study of alemtuzumab in combination with @entity3118 in @entity1 with @entity66 . @entity1 AND METHODS: @entity1 received alemtuzumab and @entity3118 daily on days 1 to 5 of a 28-day cycle for up to 6 cycles with the primary objective of determining the rate of complete response. Of 60 enrolled @entity1 , 51 had previously received @entity3118 , and 60% had received 3 or more prior therapies. RESULTS: Five @entity1 experienced complete response (8.3%) and 12 experienced partial response, yielding an overall response rate of 28.3% for the intention-to-treat population. Among the 41 @entity1 who completed at least 4 cycles of therapy, the complete response rate was 20%. Median progression-free survival was 211 days. Forty-seven percent of @entity1 experienced @entity646 , including 4 @entity1 with symptomatic @entity2803 . All @entity1 responded to antiviral therapy. CONCLUSION: Despite some evidence of efficacy in this setting, the primary end point for the study was not met. In the era of targeted agents that are well tolerated, the combination of @entity3118 and alemtuzumab should be used rarely for a select group of fit @entity1 who are refractory to standard therapies.

A Phase 2 Trial of @entity3118 Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS'] @entity2803 :: ('MESH:D003586', 'Disease') :: ['cytomegalovirus disease'] @entity646 :: ('MESH:D014766', 'Disease') :: ['cytomegalovirus viremia'] @entity66 :: ('MESH:D004194', 'Disease') :: ['relapsed disease'] @entity1072 :: ('MESH:D015451', 'Disease') :: ['chronic lymphocytic leukemia'] @entity3118 :: ('MESH:C024352', 'Chemical') :: ['fludarabine']
@entity1072 :: (MESH:D015451,Disease) :: ['Chronic Lymphocytic Leukemia']
